Acquired hemophilia A resolution in a hepatitis C virus/human immunodeficiency virus–coinfected patient with cure of hepatitis C by direct‐acting antiviral agents
Laetitia Mauge, Juliette Pavie, Dominique Batisse, Luc Darnige – 28 September 2017
Mitochondrial and anabolic pathways in hepatocellular carcinoma
Nikolai A. Timchenko – 28 September 2017
A Large‐scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma
Ping Luo, Peiyuan Yin, Rui Hua, Yexiong Tan, Zaifang Li, Gaokun Qiu, Zhenyu Yin, Xingwang Xie, Xiaomei Wang, Wenbin Chen, Lina Zhou, Xiaolin Wang, Yanli Li, Hongsong Chen, Ling Gao, Xin Lu, Tangchun Wu, Hongyang Wang, Junqi Niu, Guowang Xu – 28 September 2017 – Hepatocellular carcinoma (HCC) is the third most lethal cancer worldwide. The lack of effective biomarkers for the early detection of HCC results in unsatisfactory curative treatments. Here, metabolite biomarkers were identified and validated for HCC diagnosis.
Liver immunology: A new section for the journal
Ginny L. Bumgardner – 28 September 2017
Acquired hemophilia A resolution in a hepatitis C virus/human immunodeficiency virus–coinfected patient with cure of hepatitis C by direct‐acting antiviral agents
Laetitia Mauge, Juliette Pavie, Dominique Batisse, Luc Darnige – 28 September 2017
Distinct role of nuclear receptor corepressor 1 regulated de novo fatty acids synthesis in liver regeneration and hepatocarcinogenesis in mice
Qing Ou‐Yang, Xi‐Meng Lin, Yan‐Jing Zhu, Bo Zheng, Liang Li, Ying‐Cheng Yang, Guo‐Jun Hou, Xin Chen, Gui‐Juan Luo, Feng Huo, Qi‐Bin Leng, Frank J. Gonzalez, Xiao‐Qing Jiang, Hong‐Yang Wang, Lei Chen – 28 September 2017 – It is urgent that the means to improve liver regeneration (LR) be found, while mitigating the concurrent risk of hepatocarcinogenesis (HCG). Nuclear receptor corepressor 1 (NCoR1) is a co‐repressor of nuclear receptors, which regulates the expression level of metabolic genes; however, little is known about its potential contribution for LR and HCG.
OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma
Haithem Chtioui – 27 September 2017
Reply
Aijaz Ahmed, Rachel Beckerman, Zobair M. Younossi – 27 September 2017
Societal perspectives analysis for evaluating direct‐acting antiviral affordability while awaiting liver transplant
Xibei Liu, Yousif Elmofti, Catherine Kulaga, Brandon Gisi, Ji Won Yoo – 27 September 2017
Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C
Ezequiel Mauro, Gonzalo Crespo, Carla Montironi, Maria‐Carlota Londoño, Virginia Hernández‐Gea, Pablo Ruiz, Lydia Sastre, Julissa Lombardo, Zoe Mariño, Alba Díaz, Jordi Colmenero, Antoni Rimola, Juan Carlos Garcia‐Pagán, Mercé Brunet, Xavier Forns, Miquel Navasa – 27 September 2017 – Sustained virological response (SVR) improves survival in post‐liver transplant (LT) recurrent hepatitis C. However, the impact of SVR on fibrosis regression is not well defined.